TWI290469B - Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component - Google Patents

Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component Download PDF

Info

Publication number
TWI290469B
TWI290469B TW089113895A TW89113895A TWI290469B TW I290469 B TWI290469 B TW I290469B TW 089113895 A TW089113895 A TW 089113895A TW 89113895 A TW89113895 A TW 89113895A TW I290469 B TWI290469 B TW I290469B
Authority
TW
Taiwan
Prior art keywords
washing liquid
flowing
organic solvent
ginger
concentrated
Prior art date
Application number
TW089113895A
Other languages
Chinese (zh)
Inventor
Tian-Shung Wu
Sheng-Chu Kuo
Che-Ming Teng
Feng-Nien Ko
Original Assignee
Medical & Pharm Ind Tech & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical & Pharm Ind Tech & Dev filed Critical Medical & Pharm Ind Tech & Dev
Priority to TW089113895A priority Critical patent/TWI290469B/en
Priority to DE10128266A priority patent/DE10128266B4/en
Priority to GB0114693A priority patent/GB2366565B/en
Priority to CH01133/01A priority patent/CH692272A5/en
Priority to FR0108875A priority patent/FR2811573B1/en
Priority to JP2001211163A priority patent/JP4052819B2/en
Application granted granted Critical
Publication of TWI290469B publication Critical patent/TWI290469B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

The present invention provides a method for manufacturing component capable of efficiently preventing inflammation and platelets agglutination form ginger, which includes the steps of: (a) manufacturing a rough liquid from the rhizome of ginger (Zingiber officinale Rose) by extraction of organic solvent or distillation of water vapor; (b) guiding the rough liquid into a reverse-phase layer-separated tube for being flowed and washed sequentially by water, first flowing and washing liquid and second flowing and washing liquid, and gathering the dissolved and separated object from the first flowing and washing liquid and the dissolved and separated object from the second flowing and washing liquid, wherein the polarity of the first flowing and washing liquid is larger than that of the second flowing and washing liquid and the polarity of the second flowing and washing liquid is larger than chloroform; (c) evaporating and removing the first flowing and washing liquid in the dissolved and separated object of the first flowing and washing liquid to obtain a first dissolved and separated concentrate which can be used as the efficient component; and (d) evaporating and removing the second flowing and washing liquid in the dissolved and separated object of the second flowing and washing liquid to obtain a second dissolved and separated concentrate which can be used as the efficient component.

Description

1290469 A7 B7 五、發明說明（） 發明領域 (請先閱讀背面之注意事項再填寫本頁) 本發明係關於一種從薑製備含抗發炎或抗血小板凝集 的有效成分的產品之方法。 背景 在中國或日本，薑在食用或藥用方面都是很普遍的材 料。生薑是一般民眾日常生活中不可或缺的調味佐料，中 醫的臨床多用於發散風寒，健胃止喔，抗菌解毒，臺汁可 作爲外敷，具有消炎止痛之效（臨床實用彩色科學中藥大 典，國際中文版第一冊，76頁，立得出版社）。在沙烏地阿 拉伯，薑則用於治療嘔吐、促進消化或作爲驅風劑（Ageel W α/., 1987, Plants Used in Saudi Folk Medicine, King Saud University Press，Riyadh，ρ·400)。 經濟部智慧財產局員工消費合作社印製 近年來，許多科學硏究顯示薑具有廣泛的生理活性。 例如：含薑的複方可抑制癌症轉移（日本專利公告號碼 072581 04)、抗病毒（日本專利公告號碼071 1 861)、輔助神 經營養因子生成，改善阿茲海默症與帕金森氏症等腦部疾 病（日本專利公告號碼07025777)、抗關節炎（日本專利公 告號碼06293653、美國專利第5494668號、美國專利第 5683698號）、抗菌（日本專利公告號碼0622793 1)、鎭痛（曰 本專利公告號碼06107556)等。事實上，薑含1〜4 %揮發油， 其中約有200種物質被分離出來。在美國專利第5804603號 中提到，薑所含薑酮（zingerone)是辛辣味的主要來源，且 薑醇（gingerol)與生薑醇（shogaol)也具有辛香味。此外，薑 4 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） 經濟部智慧財產局員工消費合作社印製 1290469 A7 ___B7____ 五、發明說明（2 ) 醇有強心、抑制老鼠離體靜脈收縮、調控老鼠與兔子血管 因eic〇san〇id引起的收縮等作用，而生薑醇則可抑制血管收 縮。在Srivastava與Mustafa的硏究中顯示薑可抑制環氧化 酵素（cyclooxygenase)與脂氧化酵素（lipoxygenase)產物生 成，同時抑制 eicosanoid 的合成（Medical Hypotheses，1992, 3 9·· 342-3 48)。Mascolo Ν·等人則發現，在以 100 mg/kg的劑 量口服給藥後，薑之80 %酒精萃取物與乙醯水楊酸 (acetylsalicylic acid)對鹿角菜膠（carageenan)誘發的老鼠 腳掌浮腫的抑制效果相當，抑制率分別爲39 %與38 %。在 同一硏究中也發現，薑之80%酒精萃取物可抑制酵母所引 起的發熱，並可抑制格蘭氏陰性菌與格蘭氏陽性菌的生長 (Journal of Ethnopharmocology，1 989，27，129-140)。 • Srivastava與Mustafa以薑粉末治療56個臨床病人，結果顯 示四分之三的關節炎病人減輕疼痛或腫脹，而所有肌肉不 適的病人都感覺疼痛減輕，而在三個月到兩年半的臨床期 間，沒有病人表示有不良效果產生（1992, ibid)。 發明要旨 本發明是利用有機溶劑（乙醚、丙酮、甲醇、乙醇）或超 臨界二氧化碳萃取，或以水蒸氣蒸餾從薑 的根莖準備一粗製液，再經逆相層析法精製而得 到含有生薑醇（311(^&〇15)、薑醇（811^61<〇13)及/或去氫薑二酮 (dehydrogingerdione)的產物。這些產物經抗血小板凝集試 驗確認具有一定活性，進而經鹿角菜膠（Carrageenan)方法 5 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） (請先閱讀背面之注意事項再填寫本頁)1290469 A7 B7 V. INSTRUCTIONS () Field of the Invention (Please read the note on the back and then fill out this page) The present invention relates to a method for preparing a product containing anti-inflammatory or anti-platelet aggregation active ingredients from ginger. Background In China or Japan, ginger is a very common material in terms of consumption or medicinal use. Ginger is an indispensable seasoning in the daily life of the general public. The clinical practice of traditional Chinese medicine is mostly used for divergent cold, strong stomach and phlegm, antibacterial and detoxification, and Taiwan juice can be used as external application. It has anti-inflammatory and analgesic effects (Clinical Practical Color Science Chinese Medicine Dictionary) , International Chinese version of the first volume, 76 pages, Lied Publishing House). In Saudi Arabia, ginger is used to treat vomiting, promote digestion or act as a cyclone (Ageel W α/., 1987, Plants Used in Saudi Folk Medicine, King Saud University Press, Riyadh, ρ·400). Printing by the Intellectual Property Office of the Ministry of Economic Affairs, the Consumer Cooperatives In recent years, many scientific studies have shown that ginger has a wide range of physiological activities. For example, a compound containing ginger can inhibit cancer metastasis (Japanese Patent Publication No. 072581 04), antiviral (Japanese Patent Publication No. 071 1 861), assisted neurotrophic factor production, and improve brains such as Alzheimer's disease and Parkinson's disease. Diseases (Japanese Patent Publication No. 07025777), anti-arthritis (Japanese Patent Publication No. 06239653, US Patent No. 5494668, US Patent No. 5683698), Antibacterial (Japanese Patent Publication No. 0622793 1), and Pain (曰 Patent Notice) No. 06107556) and so on. In fact, ginger contains 1 to 4% volatile oil, of which about 200 are separated. As mentioned in U.S. Patent No. 5,804,603, ginger contains zingerone which is the main source of spicy taste, and gingerol and shogaol also have a pungent aroma. In addition, Jiang 4 paper size is applicable to China National Standard (CNS) A4 specification (210 X 297 mm) Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 1290469 A7 ___B7____ V. Invention description (2) Alcohol has a strong heart and inhibits mice from leaving Body vein contraction, regulation of contraction caused by eic〇san〇id in mice and rabbit blood vessels, and ginger alcohol can inhibit vasoconstriction. In the study of Srivastava and Mustafa, it was shown that ginger inhibits the production of cyclooxygenase and lipoxygenase products while inhibiting the synthesis of eicosanoid (Medical Hypotheses, 1992, 3 9·342-3 48). Mascolo et al. found that after oral administration at a dose of 100 mg/kg, 80% alcohol extract of ginger and acetylsalicylic acid on carageenan-induced paw swelling in mice The inhibitory effect was comparable, and the inhibition rates were 39% and 38%, respectively. In the same study, it was also found that 80% alcohol extract of ginger inhibited the fever caused by yeast and inhibited the growth of Gram-negative bacteria and Gram-positive bacteria (Journal of Ethnopharmocology, 1 989, 27, 129). -140). • Srivastava and Mustafa treated 56 clinical patients with ginger powder. The results showed that three-quarters of arthritis patients relieved pain or swelling, and all patients with muscle discomfort felt pain relief, and in three months to two and a half years of clinical During the period, no patients indicated that adverse effects were produced (1992, ibid). SUMMARY OF THE INVENTION The present invention utilizes an organic solvent (diethyl ether, acetone, methanol, ethanol) or supercritical carbon dioxide extraction, or steam distillation to prepare a crude liquid from the roots of ginger, and then refined by reverse phase chromatography to obtain ginger. The product of alcohol (311 (^ & 〇 15), gingerol (811^61 < 〇 13) and / or dehydrogingerdione. These products have been confirmed to have certain activity by anti-platelet aggregation test, and then through the antlers Carrageenan Method 5 This paper size applies to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) (please read the notes on the back and fill out this page)

A7 B7 1290469 i、發明說明（6 ) 適用於本發明方法的逆相層析管柱包括（但不限於）被 塡充有多孔性聚合物的樹脂，例如Diaion HP-20 (三菱公 司 Mitsubishi Co.)、Sephadex LH-20 (Pharmicia Co.)或 RP-18 (Nacalai tesque Co·)等逆相層析樹脂 本發明將藉以下實施例被進一步瞭解，該等實施例僅 爲說明之用而非用於限制本發明範圍。 有效成分之測定 於以下實施例中使用高效液相層析（high performance liquid chromatography，簡稱HPLC)來測定本發明方法所製 備的產品的有效成分。HPLC光譜係被記錄於一高效液相層 析儀（HPLC Shimadzu LC-10AT，Japan)，其中適量的樣品以 移動相溶液[甲腈與水（65 : 3 5，V/V)的混合液]定量至25 _ ml，經0.2 5 μιη濾膜過濾後，將濾液注入一塡充有Cosmosil 5CM 8的管柱（長25 cm，內徑4.6 mm，粒子大小5 μιη)，以 該移動相溶液進行流洗（elution)。採用紫外光偵測器 (Shimadzu SPD-6AV，Japan)，偵測溶離液（eluate)在波長 23 0 nm的吸收。 實施例一 將生薑2100 g打碎後過濾得濾液與薑殘渣。取500 ml 濾液以500 ml乙醚萃取三次，將每次萃取得到的水層與乙 醚層分離，並合倂被分離的乙醚層，揮發移除其中的乙醚 而得乙醚層濃縮物（I_〇E)。另將薑殘渣以3000 ml丙酮萃取 三次，過濾後得丙酮萃取液，將每次萃取得到丙酮萃取液 9 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） (請先閱讀背面之注意事項再填寫本頁) -------訂---------線· 經濟部智慧財產局員工消費合作社印製 1290469 A7 B7 五、發明說明（） 合倂並減壓濃縮得丙酮抽出物（1-0) 14.5 g。將乙醚層濃縮 物（I-OE)與丙酮抽出物（1-0)合倂後取7 g，注入一塡充有 180 g Diaion HP_20樹脂的逆相色層層析管柱（長度30 cm， 內徑3 cm，粒徑 5 00 μ-800 μ)，依序以 1500 ml水、25 00 ml 甲醇、2000 ml丙酮與2000 ml氯仿進行流洗（elution)，收集 水溶離物、甲醇溶離物、丙酮溶離物與氯仿溶離物，減壓 濃縮後得濃縮水溶離物（I-OW) 0.27 g、濃縮甲醇溶離物 (I-OM) 1.45 g、濃縮丙酮溶離物（I-OA) 2.68 g與濃縮氯仿 溶離物（I-OC)0·83g。其中，I-O、I-OM與I-OA中6-生薑醇、 6-薑醇與6-去氫薑二酮的含量如表一所示。 (請先閱讀背面之注意事項再填寫本頁) 表一 含量 (mg/g) 1-0 I-OM I-OA 6-生薑醇 1·10±0·14 1.15+0.0 一 6-薑醇 59·98±0·99 103·37±8·57 2.51±0.89 6-去氫薑二酮 7·68±0·42 8.9410.41 —— 訂---------線· 經濟部智慧財產局員工消費合作社印製 實施例二 將乾薑500 g打碎後直接以30 L丙酮分三次萃取（每次 10 L)，過濾後得丙酮濾液，合倂濾液並減壓濃縮得丙酮抽 出物（11-0) 24 g。取20 g丙酮抽出物，通過塡充600 g Diaion HP-20樹脂的逆相色層層析管柱，依序以4 L水、6.5 L甲 醇、15 L丙酮與5 L氯仿流洗，收集水溶離物、甲醇溶離物、 丙酮溶離物與氯仿溶離物，分別減壓濃縮後得濃縮水溶離 10 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） 1290469 A7 B7 發明說明（） 物（II-OW) 2.5 g、濃縮甲醇溶離物（II-OM) 7.1 g、濃縮丙 酮溶離物（II-OA) 6.9 g與濃縮氯仿溶離物（Π-OC) 3.5 g。其 中，11-0、II-OM與II-OA中6-生薑醇、6-薑醇與6-去氫薑二 嗣的含量如表二所示。 含量 (mg/g) 11-0 II-OM II-OA 6-生薑醇 1.98±0.00 4.96±0.00 — 6-薑醇 43.06±0.84 70.87±1.85 2.54±0·00 6-去氫薑二酮 9.33+0.85 19·15±4·57 2·35±0·28 實施例三 將乾薑10 kg打碎後以水蒸氣蒸餾5小時，將餾出物減壓 濃縮得蒸餾物（ΙΙΙ-0) 410 g。取20 g蒸餾物通過塡充600 g Diaion HP-20樹脂的逆相色層層析管柱，依序以4.5 L水、 4.5 L甲醇、3 L丙酮與5 L氯仿流洗，收集水溶離物、甲醇 溶離物、丙酮溶離物與氯仿溶離物，減壓濃縮後得濃縮水 溶離物（III-OW) 0.03 g、濃縮甲醇溶離物（III-OM) 14.5 g、 濃縮丙酮溶離物（III-OA) 0.8 5 g與濃縮氯仿溶離物（III-OC) 0.2 g。乾薑之水蒸氣蒸餾物（ΙΙΙ-0)經HPLC分析不含6-生薑 醇、6-薑醇與6-去氫薑二酮。 實施例四 取10 g粉碎乾薑以1000 ml丙酮於50°c萃取2小時，過濾 11 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） (請先閱讀背面之注意事項再填寫本頁) --------訂---------線_ 經濟部智慧財產局員工消費合作社印製 1290469 A7 _____Β7 五、發明說明（） 除去植物殘體，減壓濃縮後以真空乾燥（40°C，75 mmHg真 空度）得丙酮萃取物IV-0。產率與產物的色澤及黏度見表 — 〇 實施例五 取1 〇 g粉碎乾薑以水蒸氣蒸餾，分別將其油溶性與水溶 性萃取部分冷凍乾燥，得油溶性萃取物V-0與水溶性萃取 物V_w。產率與產物的色澤及黏度見表三。 實施例六 取10 g粉碎乾薑置於體積25 0 ml之萃取槽中，以高壓幫 浦（LEWA公司EK-1型，美國）控制超臨界C〇2壓力，設定 壓力於2500至4000 psia，溫度由熱交換機（HOTEC公司 H-24 10型’台灣）配合萃取槽外循環管路控制，維持操作溫 度於35-60°C，流速控制於45 L/min，當C02體積達到3 00 L 時，停止萃取步驟，得萃取物VI-0。產率與產物的色澤及 黏度見表三，產物的辣味成份含量見表四。 (請先閱讀背面之注意事項再填寫本頁) 訂_ · ;線· 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） A7 1290469 10 五、發明說明（） 表三 IV-0 V-O VI-0 L* 87.6 80,4 96.3 A* -9.1 -0.1 -9.6 B* 31.1 9.6 22.0 黏度(cPs) 15.6 11.8 12.1 產率(％) 3.8 2.2 3.9 * : L、A、B之値係以色差計（Σ90 color measuring system， Nippon Denshoku Inc，co·，LTD，Japan)測量’明度以 L· 表 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 示，色度以A與B表示。 表四 含量(mg/g) VI-0 6-生薑醇 17·30±0·00 6-薑醇 26.29±0.00 6-去氫薑二酮 19.20±1.19 實施例八抗血小板凝集之藥理活性評估 以EDTA (100 mM)爲抗凝劑，由兔子耳靜脈抽血（1 : 14)，將血液於90xg下離心10分鐘後，取上層富含血小板血 漿於500xg下離心10分鐘，去除上層血漿後，將血小板懸浮 於不含鈣但含2mMEDTA的Tyrode’s溶液，隨後再於500xg 下離心10分鐘，去除Tyrode’s溶液後，將血小板重新懸浮 於不含EDTA的Tyrode’s溶液，並經上述條件離心，最後將 13 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） 1290469 A7 ____Β7__ 五、發明說明（U ) (請先閱讀背面之注意事項再填寫本頁) 血小板懸浮於如下組成的緩衝液中（mM) ·· NaCl (138.6)、 KC1 (2·8)、NaHC03 (11·9)、MgCl2 (1.1)、NaH2P04 (0.3 3)、 CaCl2 (1.0)、甘油（glucose) (11.2)和牛血淸蛋白（〇·35 %)，血小板濃度則調整至每ml緩衝液中含4.5x1 Ο8個血小 板。結果列於表五。 表五、薑萃取物對花生油酸及膠原蛋白引起血小板凝集的 __ 抑制作用 處理 抑制50%凝集作用所需的濃度(Mg/mi) 花生油酸 膠原蛋白 1-0 3.8土0.8 5.5±0.4 I-OM 1·7±0·3 2·7±0·4 11-0 3·1±0·5 6 · 5 ± 1 · 2 II-OA 10·9±3·2 21.8±2.2 II-OC 6·9±0·7 16.6±4·3 II-OM 2.0±0.2 6.9±2.4 經濟部智慧財產局員工消費合作社印制农 1·將血小板與溶媒或薑萃取物於37°C下溫熱3分鐘，隨後加 入花生油酸（1〇〇 μΜ)或膠原蛋白（10 pg/ml)引起血小板凝 集，6分鐘後當反應達到最大時，記錄血小板凝集程度，萃 取物對血小板的抑制百分比以下列方式計算： [(控制組凝集程度-實驗組凝集程度)/(控制組凝集程度)]χ100% 2.表中數據的η値爲3至5。 實施例九抗浮腫之藥理活性評估 14 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐)' A7 1290469 B7_ 五、發明說明（12 ) 抗浮腫活性係依據Winter，C· A.等人的方法加以評估 (Winter C. A. et aL, Proc. Soc. Exper. Biol. Med. Ill: 544-547, 1962·)，其內容如下： 將150±20 g的公Wistar大鼠隔夜禁食後，於左腳掌打入 鹿角菜膠（Carrageenan) (0.1 ml, 1 % 懸浮液（suspension))， 隨後立即將溶媒或待測樣品（1 0 mg/paw)均勻塗抹於左後 腳掌上，三小時後，後腳掌體積以體積描記器（Cat· #7150, UGO Basil，Italy)加以測量，並以左腳掌體積減去右腳掌 體積作爲浮腫程度的指標。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 5 11 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐） 69 04 912 A7 B7 發明說明（ 13 處理 表六 【萃取物之抗浮腫活性 iVAVAV^VVWwvAWAWAWAMAVAWAWW.WAWWAWIAWAWAWAWWWWAVliVrtVVrtWVWywV.VAWVYrtpVIAVrtVW 劑量 浮腫抑制（Μ (mg/paw) (Inhibition on carrageenan edema) 1-0 10 18 I-OE 10 19 I-OM 10 29 1-0 A 10 25 11-0 10 18 ii-ow 10 0 Π-0Μ 10 26 II-0A 10 25 11： 0C 10 8 ΙΙΙ-0 10 0 III-0M 10 11 III-0A 10 15 [6] -dehydrogingedione 26 (技明先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1. 抑制浮腫的百分比以下列方式計算： [(控制組老鼠浮腫程度)-(實驗組老鼠浮腫程度)/(控制組老鼠浮腫程度)]χΐ〇〇% 2. 表中數據爲3至6隻老鼠的平均値。 本紙張尺度適用中國國家標準（CNS)A4規格（210 X 297公釐）A7 B7 1290469 i. Description of the invention (6) A reverse phase chromatography column suitable for use in the method of the invention includes, but is not limited to, a resin that is filled with a porous polymer, such as Diaion HP-20 (Mitsubishi Co., Mitsubishi Corporation). The reverse phase chromatography resin such as Sephadex LH-20 (Pharmicia Co.) or RP-18 (Nacalai tesque Co.) is further understood by the following examples, which are for illustrative purposes only and are not intended to be used To limit the scope of the invention. Determination of Active Components In the following examples, high performance liquid chromatography (HPLC) was used to determine the active ingredients of the products prepared by the method of the present invention. The HPLC spectrum was recorded on a high performance liquid chromatograph (HPLC Shimadzu LC-10AT, Japan) in which the appropriate amount of the sample was a mobile phase solution [mixture of carbonitrile and water (65: 3 5, V/V)] Quantitatively to 25 _ ml, filtered through a 0.2 5 μηη filter, and then poured into a column packed with Cosmosil 5CM 8 (length 25 cm, inner diameter 4.6 mm, particle size 5 μιη), with the mobile phase solution Elution. The absorption of the elution solution (eluate) at a wavelength of 23 0 nm was detected using an ultraviolet light detector (Shimadzu SPD-6AV, Japan). Example 1 2100 g of ginger was crushed and filtered to obtain a filtrate and a ginger residue. 500 ml of the filtrate was extracted three times with 500 ml of diethyl ether, and the aqueous layer obtained by each extraction was separated from the ether layer, and the separated ether layer was combined and evaporated to remove the diethyl ether to obtain a diethyl ether layer concentrate (I_〇E). ). The ginger residue is extracted three times with 3000 ml of acetone, and the acetone extract is obtained by filtration. Each extraction is carried out to obtain an acetone extract. 9 The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) (please read first) Precautions on the back side of this page) -------Book---------Line · Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1290469 A7 B7 V. Invention Description () Concentration under reduced pressure gave acetone extract (1-0) 14.5 g. The diethyl ether layer concentrate (I-OE) and the acetone extract (1-0) were combined, and 7 g was taken, and a reverse phase chromatography column (length 30 cm) filled with 180 g of Diaion HP_20 resin was injected. An inner diameter of 3 cm and a particle size of 00 μ-800 μ), followed by elution with 1500 ml of water, 25 00 ml of methanol, 2000 ml of acetone and 2000 ml of chloroform, and collecting water-soluble, methanol-soluble, Acetone dissolving and chloroform dissolving, concentrated under reduced pressure to obtain concentrated water soluble (I-OW) 0.27 g, concentrated methanol dissolved (I-OM) 1.45 g, concentrated acetone dissolving (I-OA) 2.68 g and concentrated Chloroformate (I-OC) 0·83 g. Among them, the contents of 6-gingerol, 6-gingerol and 6-dehydroglycanedione in I-O, I-OM and I-OA are shown in Table 1. (Please read the notes on the back and fill out this page.) Table 1 Content (mg/g) 1-0 I-OM I-OA 6-Ginger Alcohol 1·10±0·14 1.15+0.0 A 6-Gingerol 59·98±0·99 103·37±8·57 2.51±0.89 6-dehydroglycinedion 7.68±0·42 8.9410.41 —— order---------Line· Ministry of Economic Affairs The Intellectual Property Bureau employee consumption cooperative printed the second example. After crushing 500 g of dried ginger, it was directly extracted with 30 L of acetone (10 L each time). After filtration, the acetone filtrate was obtained, and the filtrate was combined and concentrated under reduced pressure to obtain acetone. (11-0) 24 g. 20 g of acetone extract was taken and washed by a reverse phase chromatography column packed with 600 g of Diaion HP-20 resin, followed by 4 L of water, 6.5 L of methanol, 15 L of acetone and 5 L of chloroform to collect water. Dissolve, methanol dissolvate, acetone dissolvate and chloroform dissolvate, respectively concentrated under reduced pressure to obtain concentrated water dissolving 10 paper scale applicable to China National Standard (CNS) A4 specification (210 X 297 mm) 1290469 A7 B7 Description of invention ( (II-OW) 2.5 g, concentrated methanol dissolvate (II-OM) 7.1 g, concentrated acetone dissolvate (II-OA) 6.9 g and concentrated chloroform dissolvate (Π-OC) 3.5 g. Among them, the contents of 6-gingerol, 6-gingerol and 6-dehydrohydrogenin in 11-0, II-OM and II-OA are shown in Table 2. Content (mg/g) 11-0 II-OM II-OA 6-Ginger alcohol 1.98±0.00 4.96±0.00 — 6-gingerol 43.06±0.84 70.87±1.85 2.54±0·00 6-dehydroglycined ketone 9.33 +0.85 19·15±4·57 2·35±0·28 In the third example, 10 kg of dried ginger was crushed and distilled by steam for 5 hours, and the distillate was concentrated under reduced pressure to obtain a distillate (ΙΙΙ-0) 410. g. 20 g of distillate was passed through a reverse phase chromatography column packed with 600 g of Diaion HP-20 resin, sequentially washed with 4.5 L of water, 4.5 L of methanol, 3 L of acetone and 5 L of chloroform to collect water-soluble extracts. , methanol dissolving, acetone dissolving and chloroform dissolving, concentrated under reduced pressure to obtain concentrated water soluble (III-OW) 0.03 g, concentrated methanol dissolved (III-OM) 14.5 g, concentrated acetone dissolved (III-OA 0.8 g of concentrated chloroform (III-OC) 0.2 g. The steam distillate of dried ginger (ΙΙΙ-0) was analyzed by HPLC without 6-gingerol, 6-gingerol and 6-dehydroglycoledione. Example 4: 10 g of crushed ginger was extracted with 1000 ml of acetone at 50 ° C for 2 hours, and filtered. 11 paper scales were applicable to China National Standard (CNS) A4 specification (210 X 297 mm) (please read the back note first) Fill in this page) --------Book --------- Line _ Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed 1290469 A7 _____Β7 V. Invention Description () Remove plant debris, minus After concentration by pressure, the acetone extract IV-0 was obtained by vacuum drying (40 ° C, 75 mmHg vacuum). The yield and the color and viscosity of the product are shown in the table - 〇 Example 5 taken 1 〇g pulverized ginger is steam distilled, and the oil-soluble and water-soluble extract portions are freeze-dried to obtain an oil-soluble extract V-0 and water-soluble. Sexual extract V_w. The color and viscosity of the product and the product are shown in Table 3. In the sixth embodiment, 10 g of pulverized ginger is placed in an extraction tank having a volume of 25 ml, and the pressure of the supercritical C〇2 is controlled by a high pressure pump (LEWA EK-1 type, USA), and the pressure is set at 2500 to 4000 psia. The temperature is controlled by the heat exchanger (HOTEC H-24 10 type 'Taiwan) with the outer circulation line of the extraction tank, maintaining the operating temperature at 35-60 ° C, the flow rate is controlled at 45 L / min, when the volume of C02 reaches 300 L The extraction step was stopped and the extract VI-0 was obtained. The color and viscosity of the product and the product are shown in Table 3. The content of the spicy component of the product is shown in Table 4. (Please read the note on the back and then fill out this page) _ · ; Line · Ministry of Economic Affairs Intellectual Property Bureau Employees Consumption Cooperative Printed This paper scale applies China National Standard (CNS) A4 specification (210 X 297 mm) A7 1290469 10 V. INSTRUCTIONS () Table III IV-0 VO VI-0 L* 87.6 80,4 96.3 A* -9.1 -0.1 -9.6 B* 31.1 9.6 22.0 Viscosity (cPs) 15.6 11.8 12.1 Yield (%) 3.8 2.2 3.9 * : The enthalpy of L, A, and B is measured by a color difference meter (Σ90 color measuring system, Nippon Denshoku Inc, co., LTD, Japan). 'Lightness is L. Table (please read the back note first and then fill in this page) Printed by the Consumers' Cooperative of the Intellectual Property Office of the Ministry of Economic Affairs, the chromaticity is indicated by A and B. Table IV Content (mg/g) VI-0 6-Ginger Alcohol 17.30±0·00 6-Gingerol 26.29±0.00 6-Dehydrogenated Dione 19.20±1.19 Example 8 Evaluation of Pharmacological Activity of Antiplatelet Aggregation Using EDTA (100 mM) as an anticoagulant, blood was drawn from the rabbit ear vein (1:14), and the blood was centrifuged at 90xg for 10 minutes. The upper platelet-rich plasma was centrifuged at 500xg for 10 minutes to remove the upper plasma. Platelets were suspended in Tyrode's solution containing no calcium but containing 2 mM EDTA, followed by centrifugation at 500 xg for 10 minutes. After removing Tyrode's solution, the platelets were resuspended in TYTA-free Tyrode's solution, and centrifuged under the above conditions, and finally 13 This paper scale is applicable to China National Standard (CNS) A4 specification (210 X 297 mm). 1290469 A7 ____Β7__ V. Invention description (U) (Please read the note on the back and fill in this page) Platelets are suspended in the following buffer Medium (mM) · · NaCl (138.6), KC1 (2·8), NaHC03 (11·9), MgCl2 (1.1), NaH2P04 (0.3 3), CaCl2 (1.0), glycerol (11.2) and bovine blood Prion protein (〇·35%), platelet concentration is adjusted to buffer per ml 4.5x1 Ο8 containing a platelet. The results are shown in Table 5. Table 5, __ Inhibition of ginger extract on platelet aggregation caused by peanut oleic acid and collagen Treatment concentration required to inhibit 50% agglutination (Mg/mi) Peanut oleic acid collagen 1-0 3.8 soil 0.8 5.5±0.4 I- OM 1·7±0·3 2·7±0·4 11-0 3·1±0·5 6 · 5 ± 1 · 2 II-OA 10·9±3·2 21.8±2.2 II-OC 6· 9±0·7 16.6±4·3 II-OM 2.0±0.2 6.9±2.4 Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperative Printed Agriculture 1. Warm platelets and vehicle or ginger extract at 37 °C for 3 minutes. Subsequently, peanut oleic acid (1 μμΜ) or collagen (10 pg/ml) was added to cause platelet aggregation, and when the reaction reached a maximum after 6 minutes, the degree of platelet aggregation was recorded, and the percentage inhibition of the platelet by the extract was calculated in the following manner: (degree of agglutination in the control group - degree of agglutination in the experimental group) / (degree of agglutination in the control group)] χ 100% 2. The η 数据 of the data in the table is 3 to 5. Example 9 Evaluation of pharmacological activity against edema 14 This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm)' A7 1290469 B7_ V. Description of invention (12) Anti-edema activity is based on Winter, C·A The method of et al. was evaluated (Winter CA et aL, Proc. Soc. Exper. Biol. Med. Ill: 544-547, 1962·), which reads as follows: 150 ± 20 g of male Wistar rats were fasted overnight Then, in the left foot, enter Carrageenan (0.1 ml, 1% suspension), then immediately apply the solvent or test sample (10 mg/paw) evenly on the left hind foot, three hours. Thereafter, the posterior foot volume was measured with a plethysmograph (Cat·#7150, UGO Basil, Italy), and the volume of the left foot was subtracted from the volume of the right foot as an indicator of the degree of edema. (Please read the notes on the back and fill out this page.) Printed by the Ministry of Economic Affairs, Intellectual Property Office, Staff and Consumer Cooperatives. 5 11 This paper scale applies to China National Standard (CNS) A4 specification (210 X 297 mm) 69 04 912 A7 B7 Invention Description (13 Treatment Table 6 [Anti-edema activity of extracts iVAVAV^VVWwvAWAWAWAMAVAWAWW.WAWWAWIAWAWAWAWWWVVVVVVVrtWVWywV.VAWVYrtpVIAVrtVW Dose edema inhibition (Μ/mg (Inhibition on carrageenan edema) 1-0 10 18 I-OE 10 19 I-OM 10 29 1-0 A 10 25 11-0 10 18 ii-ow 10 0 Π-0Μ 10 26 II-0A 10 25 11: 0C 10 8 ΙΙΙ-0 10 0 III-0M 10 11 III-0A 10 15 [6] -dehydrogingedione 26 (Technology first read the back of the note and then fill out this page) Ministry of Economic Affairs Intellectual Property Bureau employee consumption cooperative printing 1. The percentage of inhibition of edema is calculated in the following way: [(control group mouse edema degree) - (experimental group The degree of edema in mice) / (degree of edema in control group)] χΐ〇〇% 2. The data in the table is the average 値 of 3 to 6 mice. This paper scale applies to Chinese National Standard (CNS) A4 specification (210 X 297 mm). )

Claims (1)

^ 1290469 申請專利範圍: %年&月β日ίΚ寬丨正本丨 ，一一…(册7年5月#fe) 1_ 一種從薑製備含抗發炎或抗血小板凝集的有效 成分的產品之方法，包含下列步驟： a) 從薑（^7/7^/心，We)的根莖製備一粗製液； b) 將該粗製液導入一逆相層析管柱，並依序以水、第 一流洗液及第二流洗液流洗，收集其中的第一流洗液的溶 離物及第二流洗液的溶離物，其中該第一流洗液的極性大 於該第二流洗液，該第二流洗液的極性大於氯仿；及^ 1290469 Patent application scope: %年&月β日ίΚ宽丨正本丨,一一...(册七年月#fe) 1_ A method for preparing a product containing anti-inflammatory or anti-platelet aggregation active ingredients from ginger , comprising the steps of: a) preparing a crude liquid from the rhizome of ginger (^7/7^/heart, We); b) introducing the crude liquid into a reverse phase chromatography column, followed by water, first flow The washing liquid and the second flowing washing liquid are washed, and the dissolved matter of the first flowing washing liquid and the second flowing washing liquid are collected, wherein the first flowing washing liquid has a polarity greater than the second flowing washing liquid, and the second The flow washing liquid is more polar than chloroform; and c) 揮發移除該第一流洗液的溶離物中的第一流洗液而 得一第一濃縮溶離物，該第一濃縮溶離物可作爲該產品被 取出；及 d) 揮發移除該第二流洗液的溶離物中的第二流洗液而 得一第二濃縮溶離物，該第二濃縮溶離物可作爲該產品被 取出， 其中該步驟a)包含下列步驟i)至iv)，或步驟I)，或步 驟Γ)，或步驟I”），該步驟i)至iv)爲：c) volatilizing to remove the first stream of the first flowing lotion to obtain a first concentrated dissolvate, the first concentrated dissolving material can be taken out as the product; and d) volatilizing to remove the second Flowing a second stream of the wash liquor to obtain a second concentrated solvent, the second concentrated solvent being removed as the product, wherein step a) comprises the following steps i) to iv), or Step I), or step Γ), or step I"), the steps i) to iv) are: i) 將蔓的新鮮根莖粉碎及過濃， 而得到一濾液及一殘渣部份； ii) 將該濾液以一第一有機溶劑萃取，取出所獲得的第 一有機溶劑萃取液，並揮發移除其中的第一有機溶劑而獲 得一濃縮的第一有機溶劑萃取液； iii) 將該殘渣部份以一第二有機溶劑萃取，取出所獲 得的第二有機溶劑萃取液，並揮發移除其中的第二有機溶 劑而獲得一濃縮的第二有機溶劑萃取液；及 iv) 合倂該濃縮的第一有機溶劑萃取液及該濃縮的第二 -17- 1290469 _ (2007年8月修正) 有機溶劑萃取液而獲得該粗製液； 該步驟I)爲： I)以前述步驟iii)的第二有機溶劑萃取被粉碎的薑 的乾燥根莖，取出所獲得的第二有機 溶劑萃取液，並揮發移除其中的第二有機溶劑而獲得該粗 製液；及i) pulverizing and over-concentrating the fresh rhizome of the vine to obtain a filtrate and a residue fraction; ii) extracting the filtrate as a first organic solvent, taking out the obtained first organic solvent extract, and evaporating and removing a first organic solvent to obtain a concentrated first organic solvent extract; iii) extracting the residue portion with a second organic solvent, taking out the obtained second organic solvent extract, and volatilizing and removing the same a second organic solvent to obtain a concentrated second organic solvent extract; and iv) a combined first concentrated organic solvent extract and the concentrated second 170-1290469 (revised August 2007) organic solvent The extract is obtained to obtain the crude liquid; the step I) is: I) extracting the dried rhizome of the pulverized ginger with the second organic solvent of the aforementioned step iii), taking out the obtained second organic solvent extract, and evaporating and removing The second organic solvent is used to obtain the crude liquid; and 該步驟Γ)爲： Γ)以水蒸氣蒸飽被粉碎的薑 燥根莖，減壓濃縮所獲得的餾出物而獲得該粗製液；及 該步驟I”）爲： I”）以超臨界二氧化碳萃取被粉碎的薑（Zhf/心r 的乾燥根莖，並揮發移除其中的二氧化碳而獲 得該粗製液。The step Γ) is: Γ) steaming the pulverized dried ginger roots with steam, and concentrating the obtained distillate under reduced pressure to obtain the crude liquid; and the step I") is: I") with supercritical carbon dioxide The dried rhizome of the pulverized ginger (Zhf/heart r) is extracted, and the carbon dioxide therein is volatilized to obtain the crude liquid. 2. 如申請專利範圍第1項的方法，其中該含抗發炎 或抗血小板凝集的有效成分的產品包含0.5 - 10 mg/g的生 薑醇（shogaol)，1 - 150 mg/g 的薑醇（6-gingerol)及 1.0 - 40 mg/g的 6-去氫薑二酮（6-dehydrogingerdione)。 3· 如申請專利範圍第1或2項的方法，其中該第一 流洗液爲甲醇及該第二流洗液爲丙酮。 4. 如申請專利範圍第3項的方法，其中的步驟〇包 含步驟i)至i v)。 -18- 1290469 (2007年8月修正) 5. 如申請專利範圍第4項的方法： 溶劑爲乙醚。 6. 如申請專利範圍第4項的方法 溶劑爲丙酮、甲醇、乙醇或其等之混合| 7. 如申請專利範圍第6項的方法 溶劑爲丙酮。 8. 如申請專利範圍第3項的方法 含步驟I)。 9. 如申請專利範圍第8項的方法； 溶劑爲丙酮、甲醇、乙醇或其等之混合\ 10. 如申請專利範圍第9項的方法， 溶劑爲丙酮。 11. 如申請專利範圍第3項的方法， 含步驟Γ)。 12. 如申請專利範圍第3項的方法， 含步驟Γ)。 其中該第一有機 其中該第二有機 其中該第二有機 其中的步驟a)包 其中該第二有機 其中該第二有機 其中的步驟a)包 其中的步驟a)包 > 1290469 ‘ (2007年8月修正) 13. 如申請專利範圍第1項的方法，其中的逆相層析 管柱被塡充有多孔性聚合物的樹脂。2. The method of claim 1, wherein the product comprising an anti-inflammatory or anti-platelet aggregation active ingredient comprises 0.5 - 10 mg/g of shogaol, 1 - 150 mg/g of gingerol (6-gingerol) and 1.0 - 40 mg/g of 6-dehydrogingerdione. 3. The method of claim 1 or 2, wherein the first stream washing liquid is methanol and the second stream washing liquid is acetone. 4. The method of claim 3, wherein the steps include steps i) through i v). -18- 1290469 (Amended in August 2007) 5. Method of applying for patent item 4: The solvent is diethyl ether. 6. For the method of claim 4, the solvent is acetone, methanol, ethanol or the like. 7. The method of claim 6 is acetone. 8. The method of claim 3 includes step I). 9. The method of claim 8 of the patent application; the solvent is a mixture of acetone, methanol, ethanol or the like. 10. The method of claim 9, wherein the solvent is acetone. 11. For the method of applying for the third item of the patent scope, including the step Γ). 12. The method of applying for the third item of the patent scope, including the step Γ). Wherein the first organic wherein the second organic wherein the second organic step a) comprises the second organic wherein the second organic step a) of which comprises a) package > 1290469 ' (2007 Amendment in August) 13. The method of claim 1, wherein the reverse phase chromatography column is filled with a resin of a porous polymer. -20--20-
TW089113895A 2000-07-12 2000-07-12 Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component TWI290469B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
TW089113895A TWI290469B (en) 2000-07-12 2000-07-12 Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component
DE10128266A DE10128266B4 (en) 2000-07-12 2001-06-12 Process for the preparation of an extract from Zingiber officinale
GB0114693A GB2366565B (en) 2000-07-12 2001-06-15 Extract potent in anti-inflammation, anti-platelet aggregation and anti-fungal activity from Zingiber Officinale and pharmaceuticals containing said extract
CH01133/01A CH692272A5 (en) 2000-07-12 2001-06-21 A process for producing an extract having strong Antiinflammations-, Antiblutplättchenaggregations- and antifungal activity of Zingiber officinale and pharmaceutical compositions
FR0108875A FR2811573B1 (en) 2000-07-12 2001-07-04 PROCESS FOR THE PREPARATION OF A POWERFUL EXTRACT OF ANTI-INFLAMMATORY ACTIVITIES, PLATELET AND ANTIFUNGAL ANTI-AGGREGATION FROM OFFICINAL ZINGIBER AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID EXTRACT
JP2001211163A JP4052819B2 (en) 2000-07-12 2001-07-11 Method for producing extract containing ginger active ingredient, and pharmaceutical composition containing the extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW089113895A TWI290469B (en) 2000-07-12 2000-07-12 Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component

Publications (1)

Publication Number Publication Date
TWI290469B true TWI290469B (en) 2007-12-01

Family

ID=21660367

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089113895A TWI290469B (en) 2000-07-12 2000-07-12 Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component

Country Status (6)

Country Link
JP (1) JP4052819B2 (en)
CH (1) CH692272A5 (en)
DE (1) DE10128266B4 (en)
FR (1) FR2811573B1 (en)
GB (1) GB2366565B (en)
TW (1) TWI290469B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641025A (en) * 2016-05-30 2019-04-16 西姆莱斯股份公司 Drug containing race CO2 extract

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003406A (en) * 2001-10-11 2004-06-18 Ct De Investigacion Y Desarrol Method of obtaining an extract of ginger.
JP4495406B2 (en) * 2003-04-21 2010-07-07 株式会社武蔵野免疫研究所 Sendangusa plant extract-containing composition
KR100623003B1 (en) 2004-12-22 2006-09-14 전북대학교산학협력단 Manufacturing Method of Ginger Extract using Ultrasonication
JP4849388B2 (en) * 2005-03-03 2012-01-11 国立大学法人名古屋大学 Physiologically active substance and method for producing the same, tasting method of pungent physiologically active substance, and health / medical composition
JP2008156297A (en) * 2006-12-25 2008-07-10 Hokkaido Univ Serotonin 2b and/or 2c receptor antagonist
AU2008205312B2 (en) * 2007-01-08 2013-11-21 Annji Pharmaceutical Co., Ltd. Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
GB2453728B (en) * 2007-10-16 2009-11-04 Medical & Pharmaceutical Indus Use of a potent product extracted from rhizomes of zingiber offcinale in preparation of a medicament for treatment gastritis, gastric ulcer and duodenal ulcer
US7842318B2 (en) 2007-10-18 2010-11-30 Medical And Pharmaceutical Industry Technology And Development Center Use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori
KR101481040B1 (en) 2008-03-31 2015-01-14 한국화학연구원 Composition for anti-inflammation comprising [10]-gingerdione or 1-dehydro-[10]-gingerdione
JP5103296B2 (en) * 2008-06-23 2012-12-19 花王株式会社 Method for producing purified ginger oleoresin
JP5375050B2 (en) * 2008-11-28 2013-12-25 ユーハ味覚糖株式会社 Processed ginger processed food composition and method for producing the same
ES2451346T3 (en) * 2009-01-20 2014-03-26 Indena S.P.A. Compositions comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus
ITMI20090049A1 (en) * 2009-01-20 2010-07-21 Indena Spa COMPOSITIONS BASED ON LIPOFILE EXTRACTS OF ZINGIBER OFFICINALE AND ECHINACEA ANGUSTIFOLIA FOR THE PREVENTION AND TREATMENT OF GASTRO-ESOPHAGEAL REFLOW AND CHEMOTHERAPY-INDUCED EMESIS
JP2012051811A (en) * 2010-08-31 2012-03-15 House Foods Corp Immunoenhancing agent
KR101324926B1 (en) * 2011-01-28 2013-11-01 계명대학교 산학협력단 Manufacturing Mathod of Ginger Extract And Ginger Extract Using The Same
CN102965197A (en) * 2011-09-02 2013-03-13 贵州百灵企业集团制药股份有限公司 Method for extracting and separating ginger essential oil and ginger oil resin enriched in gingerol
KR101347910B1 (en) 2012-01-31 2014-01-08 계명대학교 산학협력단 a Food Composition, a Cosmetic Composition, a Pharmaceutical Composition Comprising Supercritical Fluid Extract of Ginger and Extract of Dropwort Fermented
CN102657841A (en) * 2012-06-08 2012-09-12 桂林三金药业股份有限公司 Ginger phenols extract preparation and preparation method thereof
JP6030889B2 (en) * 2012-08-27 2016-11-24 辻製油株式会社 Method for producing composition for improving bone metabolism
CN103040713B (en) * 2012-12-29 2015-07-29 青岛华仁技术孵化器有限公司 A kind of Chinese medicine hair cream preventing and treating seborrheic alopecia, head pruritus
CN103751073B (en) * 2014-02-26 2015-04-22 广东轻工职业技术学院 Compound traditional Chinese medicine extract with function of removing dandruff, and application
EP3097905B1 (en) * 2015-05-28 2020-11-04 Symrise AG Cosmetic compositions
AU2018267649B2 (en) * 2016-04-27 2021-03-04 Vladimir Badmaev Method maintaining iron homeostasis with shogaols
CN109562046A (en) * 2016-05-30 2019-04-02 西姆莱斯股份公司 Cosmetic composition containing Clary sage lactone
KR102156700B1 (en) 2017-07-20 2020-09-16 고려대학교 세종산학협력단 Gingerol derivatives having a biofilm formation inhibiting ability and a pharmaceutical composition for preventing or treating infection caused by biofilm as an active ingredient thereof
WO2019017709A1 (en) * 2017-07-20 2019-01-24 고려대학교 세종산학협력단 Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom
JP6890801B2 (en) * 2018-06-08 2021-06-18 中野Ｂｃ株式会社 Manufacturing method of processed ginger products
KR102079065B1 (en) * 2019-08-02 2020-02-19 경희대학교 산학협력단 Pharmaceutical composition comprising dehydro-6-gingerdione for prevention or treatment of metabolic disease
CN111135135B (en) * 2020-02-11 2022-08-02 广州栋方生物科技股份有限公司 Ginger powder with mite removing and acne removing effects and preparation method and application thereof
KR102647997B1 (en) * 2021-06-15 2024-03-18 주식회사 제넨셀 Composition for preventing, improving, or treating degenerative arthritis comprising steamed ginger extract or 1-dehydro-6-gingerdione isolated therefrom as an active ingredient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6239736A (en) * 1985-08-15 1987-02-20 Chino Corp Scanning type radiation thermometer
JPS6372625A (en) * 1986-09-12 1988-04-02 Tsumura & Co Blood platelet agglutination inhibitor
CH675685A5 (en) * 1988-06-24 1990-10-31 Flachsmann Ag Emil
JPH0585931A (en) * 1991-09-26 1993-04-06 Japan Tobacco Inc Leucotrienes biosynthesis inhibitor
GB2286120B (en) * 1992-05-21 1997-01-15 Jefferey Jay Staggs Therapeutic pepper extracts and related compounds
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JPH10182346A (en) * 1996-12-27 1998-07-07 Kose Corp Cosmetic
DE19716660C2 (en) * 1997-04-22 2002-11-14 Schwabe Willmar Gmbh & Co Preparations, in particular pharmaceutical and pharmaceutical forms based on plants, for combating Helicobacter pylori infections
US6235287B1 (en) * 1998-01-09 2001-05-22 Ida Development A/S Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments
IL125316A0 (en) * 1998-07-13 1999-03-12 Dalidar Pharma Israel 1995 Ltd Novel compositions for treatment of atherosclerosis and related conditions
DE19859499C2 (en) * 1998-12-22 2002-10-24 Schwabe Willmar Gmbh & Co Stable ginger extract preparation
US6274177B1 (en) * 2000-08-26 2001-08-14 National Science Council Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641025A (en) * 2016-05-30 2019-04-16 西姆莱斯股份公司 Drug containing race CO2 extract

Also Published As

Publication number Publication date
DE10128266B4 (en) 2006-05-24
FR2811573B1 (en) 2006-05-19
CH692272A5 (en) 2002-04-30
DE10128266A1 (en) 2002-03-14
JP2002047195A (en) 2002-02-12
GB2366565A (en) 2002-03-13
JP4052819B2 (en) 2008-02-27
FR2811573A1 (en) 2002-01-18
GB2366565B (en) 2005-02-16
GB0114693D0 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
TWI290469B (en) Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component
US6274177B1 (en) Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract
JP2002501030A5 (en)
US20160151440A1 (en) A Novel Composition of Curcumin with Enhanced Bioavailability
CA2319093A1 (en) Sea cucumber carotenoid lipid fraction products and methods of use
BRPI0708826A2 (en) extracts and methods comprising cinnamon species
CN102670763A (en) Composition with auxiliary protection effect on chemical liver injury and preparation method of composition
ES2705169T3 (en) Preparation and pharmaceutical use of extract compositions of euterpe oleracea (açaí)
JP6605036B2 (en) Method for preparing a medicinal composition for preventing or treating liver and kidney damage-related diseases
TW200918085A (en) Use of a potent product extracted from rhizomes of zingiber officinale in treating a disease associated with helicobacter pylori
US20030203059A1 (en) Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from Zingiber officinal
WO2008091064A1 (en) Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases
BRPI0106382B1 (en) PROCESS FOR OBTAINING DECOCTS FROM VITIS LABRUSCA AND VITIS VINIFERA CASTS, PROCESS FOR OBTAINING THE HYDRO-ALCOHOLIC EXTRACT, PROCESS FOR OBTAINING THE HYDRO-ALCOHOLIC EXTRACT
CN100488543C (en) Local externally applied itch stopping garlic liniments
JP5773997B2 (en) Method for isolating Shimiracemart A
JP4979053B2 (en) Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract
TWI286075B (en) Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from zingiber officinal
Parkhomenko et al. Ambrosia artemisiifolia as a source of biologically active substances
CN101745011B (en) Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof
CN1279963C (en) Process for preparing product containing antiinflammatory, anticoagulant and antibacterial components from ginger and its product and medical composition
CN101745007B (en) Extraction method of 'radix ophiopogonis/ginseng and schisandra chinensis' and preparation thereof
JP2016190814A (en) Calcium permeation promoter
CN110123859A (en) Chrysanthemum leaf extract and its application with prevention and treatment hepatic injury
Yang et al. OF USE
RU2200021C1 (en) Comarum palustre l tincture, agent based on comarum palustre l and method of their preparing

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent